Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | |
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright |
| 6/6/2023 | $8.00 | Outperform | Robert W. Baird |
| 6/6/2023 | $60.00 → $80.00 | Outperform | Robert W. Baird |
| 2/28/2023 | $8.00 | Buy | H.C. Wainwright |
| 9/28/2022 | $5.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $12.00 → $14.00 | Buy | HC Wainwright & Co. |
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously
William Blair downgraded Agenus from Outperform to Mkt Perform
H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00
Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:AGEN) from Buy to Hold and raises the price target from $3 to $7.
Thursday, Agenus Inc. (NASDAQ:AGEN) announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits. Given the limited treatment options for late-stage colorectal cancer and the promising survival data from the Phase I trial of botensilimab plus balsti
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsEnergy shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares fell by 1.6%. Top Headline Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 bil
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
8-K - AGENUS INC (0001098972) (Filer)
424B5 - AGENUS INC (0001098972) (Filer)
10-Q - AGENUS INC (0001098972) (Filer)
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran
Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profiles These data advance the science of co-administration of recommended adult vaccines GSK plc (NYSE:GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines (NCT059660
BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with balstilimab (BAL), an investigational PD-1 antibody, showed clinical activity in patients with refractory sarcomas, a population with limited treatment options. "The continued activity with additional patients and longer follow-up of BOT/BAL in this study reinforces it's po
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Fireside chat will be held in-person on Thursday, September 5th at 12:45 p.m. ET in Boston, MA. A live webcast and replay will be accessible at https://cc.webcasts.com/well001/090424a_js/?entity=119_VLEQW2Q and on the Events and Presentations page of Agenus' website. HC Wainwright Global Investmen
Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in Neoadjuvant CRC Patients Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024. "Agenus milest
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations. About Agenus Agenus is a leading immuno-oncology compan